Abstract: The present invention relates to heteroleptic complexes comprising a phenylimidazole or phenyltriazole unit bonded via a carbene bond to a central metal atom, and phenylimidazole ligands attached via a nitrogen-metal bond to the central atom, to OLEDs which comprise such heteroleptic complexes, to light-emitting layers comprising at least one such heteroleptic complex, to a device selected from the group consisting of illuminating elements, stationary visual display units and mobile visual display units comprising such an OLED, to the use of such a heteroleptic complex in OLEDs, for example as emitter, matrix material, charge transport material and/or charge blocker.

Abstract: A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6?-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof.

Abstract: A method for predictive maintenance of components of an internal combustion engine by a structure-borne sound sensor includes: recording vibrations of the components of the internal combustion engine by at least one structure-borne sound sensor; and during operation of the internal combustion engine, continuously checking a release for diagnosing a wear condition of the components of the internal combustion engine. The one or more structure-borne sound sensors, which are arranged at one or more positions on the internal combustion engine, record measurement signals and forward them to evaluation electronics. The measurement signals are time-synchronized to a characteristic state of the internal combustion engine or the measurement signal recording is time-triggered. The time-synchronized or triggered measurement signals are decoded into measurement data. The decoded measurement data is subjected to a signal transformation. One or more spectrograms are generated from the signal transformation.

Abstract: A method for cooling an engine includes increasing the pressure of a liquid coolant from a first pressure to a second pressure. Thereafter, components of the engine to be cooled are contacted with the liquid coolant so that the liquid coolant at least partially evaporates and forms a vapor with a particular state. Thereafter, the vapor is fed to a throttle to reduce the pressure of the liquid coolant to a third pressure. The particular state of the vapor is determined based on the temperature and the third pressure of the liquid coolant downstream of the throttle, and based on the second pressure of the liquid coolant under an assumption that the throttle is an adiabatic throttle such that enthalpy of the liquid coolant remains constant as the liquid coolant passes the throttle. A desired vapor state adjustment is made based on the determined particular state of the vapor.

Abstract: A method for predictive maintenance of components of an internal combustion engine by a structure-borne sound sensor includes: recording vibrations of the components of the internal combustion engine by at least one structure-borne sound sensor; and during operation of the internal combustion engine, continuously checking a release for diagnosing a wear condition of the components of the internal combustion engine. The one or more structure-borne sound sensors, which are arranged at one or more positions on the internal combustion engine, record measurement signals and forward them to evaluation electronics. The measurement signals are time-synchronized to a characteristic state of the internal combustion engine or the measurement signal recording is time-triggered. The time-synchronized or triggered measurement signals are decoded into measurement data. The decoded measurement data is subjected to a signal transformation. One or more spectrograms are generated from the signal transformation.

Abstract: A pharmaceutical device for electric-field assisted administration of Tapentadol and/or of a physiologically acceptable salt thereof, the device comprising at least one pair of electrodes consisting of an active electrode and a counter electrode (1a and 2a and/or 1b and 2b), optionally at least one additional electrode as an auxiliary electrode, at least one drug reservoir (3) containing at least a portion of the Tapentadol and/or a physiologically acceptable salt thereof, and means (4) for applying the device to skin (5).

Abstract: The invention relates to a pharmaceutical patch comprising a Lidocaine constituent and a Diclofenac constituent, wherein the relative weight content ratio of the Lidocaine constituent to the Diclofenac constituent is within the range of from about 7:1 to about 4:1, based on the equivalent weight of the non-salt form of Lidocaine and of Diclofenac, for use in the local treatment or prevention of pain, wherein the pain is neuropathic pain or wherein the pain has a neuropathic pain component. The pharmaceutical composition is suitable for topical administration and local pharmacological action via delivery of Lidocaine and Diclofenac into the skin and possibly also through and to other deeper tissues such as the synovial fluid without significant systemic exposure.

Abstract: The invention relates to a pharmaceutical patch comprising a Lidocaine constituent and a Diclofenac constituent, wherein the relative weight content ratio of the Lidocaine constituent to the Diclofenac constituent is within the range of from about 7:1 to about 4:1, based on the equivalent weight of the non-salt form of Lidocaine and of Diclofenac, for use in the local treatment or prevention of pain. The pharmaceutical composition is suitable for topical administration and local pharmacological action via delivery of Lidocaine and Diclofenac into the skin and possibly also through and to other deeper tissues such as the synovial fluid without significant systemic exposure.

Abstract: A method for cooling an engine includes increasing the pressure of a liquid coolant from a first pressure to a second pressure. Thereafter, components of the engine to be cooled are contacted with the liquid coolant so that the liquid coolant at least partially evaporates and forms a vapor with a particular state. Thereafter, the vapor is fed to a throttle to reduce the pressure of the liquid coolant to a third pressure. The particular state of the vapor is determined based on the temperature and the third pressure of the liquid coolant downstream of the throttle, and based on the second pressure of the liquid coolant under an assumption that the throttle is an adiabatic throttle such that enthalpy of the liquid coolant remains constant as the liquid coolant passes the throttle. A desired vapor state adjustment is made based on the determined particular state of the vapor.

Abstract: Controlling a waste heat recovery system includes determining a difference in temperature (sensed ?T) between a working fluid (15) downstream of a first evaporator (16) and a working fluid (15) downstream of a second evaporator (20) wherein the first evaporator (16) and the second evaporator (20) are in parallel. Each receives engine exhaust gas and working fluid. At least a first valve (84) is selectively actuated to regulate flow of the working fluid into the first evaporator (16) and the second evaporator (20) responsive to the difference in temperature (sensed ?T). The first valve (84) regulates a flow of the working fluid into the first evaporator (16) and a second valve (86) regulates a flow of the working fluid into the second evaporator (20). A first feedforward signal (157) is generated for control of the first valve (84) based at least in part on the difference in temperature (sensed ?T).

Abstract: The invention is directed to an immediate release capsule which mitigates the abuse of Tapentadol or physiologically acceptable salt thereof by direct intravenous injection. The capsule comprises a tamper resistant formulation which when mixed with water and heated, results in a turbid, bubbling mixture that is not injectable with a standard insulin syringe.

Abstract: The invention relates to a pharmaceutical patch for transdermal administration of the pharmacologically active ingredient Tapentadol or a physiologically acceptable salt thereof, the patch comprising a surface layer, an adhesive layer which comprises a pressure sensitive adhesive and at least a portion of the total amount of the pharmacologically active ingredient that is contained in the pharmaceutical patch, and a removable protective layer, wherein the adhesive layer is located between the surface layer and the removable protective layer.

Abstract: The invention is directed to an immediate release capsule which mitigates the abuse of Tapentadol or physiologically acceptable salt thereof by direct intravenous injection. The capsule comprises a tamper resistant formulation which when mixed with water and heated, results in a turbid, bubbling mixture that is not injectable with a standard insulin syringe.

Abstract: A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6?-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof.

Abstract: A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6?-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof.

Abstract: The invention is directed to an immediate release capsule which mitigates the abuse of Tapentadol or physiologically acceptable salt thereof by direct intravenous injection. The capsule comprises a tamper resistant formulation which when mixed with water and heated, results in a turbid, bubbling mixture that is not injectable with a standard insulin syringe.

Abstract: A pharmaceutical device for electric-field assisted administration of Tapentadol and/or of a physiologically acceptable salt thereof, the device comprising at least one pair of electrodes consisting of an active electrode and a counter electrode (1a and 2a and/or 1b and 2b), optionally at least one additional electrode as an auxiliary electrode, at least one drug reservoir (3) containing at least a portion of the Tapentadol and/or a physiologically acceptable salt thereof, and means (4) for applying the device to skin (5).

Abstract: The invention relates to a pharmaceutical patch for transdermal administration of the pharmacologically active ingredient Tapentadol or a physiologically acceptable salt thereof, the patch comprising a surface layer, an adhesive layer which comprises a pressure sensitive adhesive and at least a portion of the total amount of the pharmacologically active ingredient that is contained in the pharmaceutical patch, and a removable protective layer, wherein the adhesive layer is located between the surface layer and the removable protective layer.

Abstract: A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6?-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof.

Abstract: A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6?-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof.